Xia Shen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xia Shen has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Jia Fan
Fudan University
36 shared publications - Jian Lin
Fudan University 2 Shanghai
36 shared publications - Jian Zhou
Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai 200032, China
36 shared publications - Jiaomeng Pan
Zhongshan Hospital 8
36 shared publications - Qiang Gao
Zhongshan Hospital 20 Shanghai
36 shared publications - Chen Sang
Fudan University 3 Shanghai
35 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Data from Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma
Metabolic reprogramming within the tumor microenvironment (TME) impairs antitumor immunity and compromises the efficacy of immunotherapy. Through multiomics-based metabolic subtyping in intrahepatic cholangiocarcinoma, we identified a subgroup with the worst prognosis that demonstrates significant enrichment in both cyclooxygenase/arachidonic acid (COX/AA) metabolism and KRAS mutations. Mechanistically, KRAS mutation–mediated NF-κB pathway activation upregulates CXCL5 expression, thereby recruiting CXCR2+ polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) into the TME. Concurrently, KRAS mutation drives prostaglandin E2 (PGE2) production in tumor cells, and PGE2, in turn, enhances AA uptake and COX-2 expression in PMN-MDSCs, establishing an amplifying loop between tumor cells and PMN-MDSCs that exacerbates PGE2 production. PGE2 accumulation potently suppresses the antitumor activity of CD8+ T cells via the prostaglandin E receptor 4 (EP4). Therapeutic targeting of the COX-2–PGE2–EP4 axis, combined with anti–PD-1 immunotherapy, demonstrates profound synergistic efficacy in both KRAS-mutant murine models and patient-derived tumor fragments harboring KRAS mutations. Significance:This work identifies a PGE2–COX-2 positive feedback loop between tumor cells and PMN-MDSCs that may serve as a therapeutic vulnerability for KRAS-mutant cholangiocarcinoma.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma
Metabolic reprogramming within the tumor microenvironment (TME) impairs antitumor immunity and compromises the efficacy of immunotherapy. Through multiomics-based metabolic subtyping in intrahepatic cholangiocarcinoma, we identified a subgroup with the worst prognosis that demonstrates significant enrichment in both cyclooxygenase/arachidonic acid (COX/AA) metabolism and KRAS mutations. Mechanistically, KRAS mutation–mediated NF-κB pathway activation upregulates CXCL5 expression, thereby recruiting CXCR2+ polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) into the TME. Concurrently, KRAS mutation drives prostaglandin E2 (PGE2) production in tumor cells, and PGE2, in turn, enhances AA uptake and COX-2 expression in PMN-MDSCs, establishing an amplifying loop between tumor cells and PMN-MDSCs that exacerbates PGE2 production. PGE2 accumulation potently suppresses the antitumor activity of CD8+ T cells via the prostaglandin E receptor 4 (EP4). Therapeutic targeting of the COX-2–PGE2–EP4 axis, combined with anti–PD-1 immunotherapy, demonstrates profound synergistic efficacy in both KRAS-mutant murine models and patient-derived tumor fragments harboring KRAS mutations. Significance:This work identifies a PGE2–COX-2 positive feedback loop between tumor cells and PMN-MDSCs that may serve as a therapeutic vulnerability for KRAS-mutant cholangiocarcinoma.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1-S8 from Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma
Figures S1-S8 and their figure legends. Figure S1. Validation of metabolic subgroups and their related properties; Figure S2. Associations between PMN-MDSC infiltration and COX/AA metabolism; Figure S3. KRAS mutation promotes an immunosuppressive TME in iCCA; Figure S4. KRAS mutation activates NF-κB signaling to promote chemotaxis of neutrophils through CXCL5-CXCR2 axis; Figure S5. AA supplementation promotes the progression of KRAS MUT iCCA; Figure S6. PMN-MDSC-derived PGE2 suppresses CD8+ T cells via EP4 to circumvent ICB efficacy; Figure S7. The COX/AA metabolism serves as a predictive biomarker for patient response to ICB therapy; Figure S8. Graphic abstract of this study.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1-S8 from Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma
Figures S1-S8 and their figure legends. Figure S1. Validation of metabolic subgroups and their related properties; Figure S2. Associations between PMN-MDSC infiltration and COX/AA metabolism; Figure S3. KRAS mutation promotes an immunosuppressive TME in iCCA; Figure S4. KRAS mutation activates NF-κB signaling to promote chemotaxis of neutrophils through CXCL5-CXCR2 axis; Figure S5. AA supplementation promotes the progression of KRAS MUT iCCA; Figure S6. PMN-MDSC-derived PGE2 suppresses CD8+ T cells via EP4 to circumvent ICB efficacy; Figure S7. The COX/AA metabolism serves as a predictive biomarker for patient response to ICB therapy; Figure S8. Graphic abstract of this study.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma
Subgroup-associated characteristics and qRT-PCR primers.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma
Subgroup-associated characteristics and qRT-PCR primers.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma
Differences of the metabolic pathways among indicated cell subsets.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma
Differences of the metabolic pathways among indicated cell subsets.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma
Differential gene expression in AY vs. AYK tumor-derived PMN-MDSCs and related sequences.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma
Differential gene expression in AY vs. AYK tumor-derived PMN-MDSCs and related sequences.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma
Expression of chemokines and chemokine receptors in KRAS MUT versus KRAS WT samples.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma
Expression of chemokines and chemokine receptors in KRAS MUT versus KRAS WT samples.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma
The expression variations of COX/AA metabolic pathway genes.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma
The expression variations of COX/AA metabolic pathway genes.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma
Supplementary Table 6 from Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma
Supplementary Table 6 from Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 7 from Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma
Full sample sizes (n), exact P values, and effect sizes are presented across the figures.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 7 from Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS-Mutant Cholangiocarcinoma
Full sample sizes (n), exact P values, and effect sizes are presented across the figures.
- Open Access
- 6 July 2026
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 25 (1)
Joint association of Insulin resistance and frailty index with incident ASCVD and MACE in individuals with cardiovascular-kidney-metabolic syndrome stages 0–3: a multi-cohort study
While insulin resistance (IR) and frailty are mechanistically intertwined via shared pathways of chronic inflammation and metabolic dysregulation, their synergistic impact on cardiovascular risk has yet to be fully elucidated. We aimed to evaluate the joint association of IR and frailty index (FI) with the risk of incident atherosclerotic cardiovascular disease (ASCVD) and major adverse cardiovascular events (MACE) in individuals with Cardiovascular-Kidney-Metabolic (CKM) syndrome stages 0-3. This study enrolled 259,714 and 2632 CKM syndrome stages 0-3 from the UK Biobank (UKB), and China Health and Retirement Longitudinal Study (CHARLS). Three IR-related indices, namely the triglyceride-glucose index (TyG), metabolic score for IR (METS-IR), and estimated glucose disposal rate (eGDR), were each combined with two frailty assessments, the FI and physical FI (PFI), yielding six composite IR-FI indices for analysis. In the UKB, MACE and ASCVD were the co-primary outcomes, with heart disease and stroke as secondary outcomes. In the CHARLS, the outcomes included CVD, heart disease, and stroke. Multivariate Cox proportional hazards models, restricted cubic spline analyses, Kaplan-Meier analyses and time-dependent receiver operating characteristic curves were employed to assess associations. Mediation analysis and functional proteomic enrichment provided a framework for exploring the potential biological mechanisms. In the UKB, elevated levels of the IR-FI were associated with increased risks of ASCVD and MACE, with consistent findings observed for CVD, heart disease, and stroke in the CHARLS. Significant positive nonlinear relationships were established for the METS-IR-FI and eGDR-FI regarding cardiovascular outcomes. Mediation analysis revealed that Creactive protein, neutrophils, and leucocyte partially mediated these associations (ratio range: 1.5-12%). Proteomic analyses identified Cytokine-cytokine receptor interaction as a primary regulatory hub, while leukocyte migration, chemotaxis, and neutrophil degranulation were characterized as the central pathological execution mechanisms in this process. The IR-FI are significantly associated with the incidence of cardiovascular events, an association that appears to be mediated through systemic inflammatory pathways. These novel integrated indices represent promising biomarkers for early screening and targeted clinical intervention among individuals with CKM syndrome stages 0-3.
- 6 July 2026
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 25 (1)
Open AccessJoint association of Insulin resistance and frailty index with incident ASCVD and MACE in individuals with cardiovascular-kidney-metabolic syndrome stages 0–3: a multi-cohort study
While insulin resistance (IR) and frailty are mechanistically intertwined via shared pathways of chronic inflammation and metabolic dysregulation, their synergistic impact on cardiovascular risk has yet to be fully elucidated. We aimed to evaluate the joint association of IR and frailty index (FI) with the risk of incident atherosclerotic cardiovascular disease (ASCVD) and major adverse cardiovascular events (MACE) in individuals with Cardiovascular-Kidney-Metabolic (CKM) syndrome stages 0-3. This study enrolled 259,714 and 2632 CKM syndrome stages 0-3 from the UK Biobank (UKB), and China Health and Retirement Longitudinal Study (CHARLS). Three IR-related indices, namely the triglyceride-glucose index (TyG), metabolic score for IR (METS-IR), and estimated glucose disposal rate (eGDR), were each combined with two frailty assessments, the FI and physical FI (PFI), yielding six composite IR-FI indices for analysis. In the UKB, MACE and ASCVD were the co-primary outcomes, with heart disease and stroke as secondary outcomes. In the CHARLS, the outcomes included CVD, heart disease, and stroke. Multivariate Cox proportional hazards models, restricted cubic spline analyses, Kaplan-Meier analyses and time-dependent receiver operating characteristic curves were employed to assess associations. Mediation analysis and functional proteomic enrichment provided a framework for exploring the potential biological mechanisms. In the UKB, elevated levels of the IR-FI were associated with increased risks of ASCVD and MACE, with consistent findings observed for CVD, heart disease, and stroke in the CHARLS. Significant positive nonlinear relationships were established for the METS-IR-FI and eGDR-FI regarding cardiovascular outcomes. Mediation analysis revealed that Creactive protein, neutrophils, and leucocyte partially mediated these associations (ratio range: 1.5-12%). Proteomic analyses identified Cytokine-cytokine receptor interaction as a primary regulatory hub, while leukocyte migration, chemotaxis, and neutrophil degranulation were characterized as the central pathological execution mechanisms in this process. The IR-FI are significantly associated with the incidence of cardiovascular events, an association that appears to be mediated through systemic inflammatory pathways. These novel integrated indices represent promising biomarkers for early screening and targeted clinical intervention among individuals with CKM syndrome stages 0-3.